| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| OCUL | OCUL | Shares | USD | XNMS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| OCUL | OCUL | Shares | USD | XNMS |
Ocular Therapeutix, Inc. develops therapies for retinal diseases, focusing on reducing the treatment burden for patients. Its lead investigational product, AXPAXLI™ (OTX-TKI), is an axitinib hydrogel administered by intravitreal injection and is in Phase 3 clinical trials for wet age-related macular degeneration (AMD). The company aims to improve long-term vision preservation for patients affected by retinal conditions such as diabetic retinopathy and retinal vein occlusion.
No recent RNS announcements for OCUL across OCUL.
No recent RNS announcements for OCUL across OCUL.